文献速递传染病防控与疫情报告营养与食品安全卫生政策与健康促进

疫苗作为应对副溶血弧菌与对虾急性肝胰腺坏死病战略手段的综合综述

Vaccines as a strategic approach to combat Vibrio parahaemolyticus and control of early mortality syndrome sin shrimp aquaculture: A comprehensive review.
PubMed 文献 · Vaccine · 2025-12-02

本文综述2009至2025年全球报告,分析疫苗防控对虾副溶血弧菌与急性肝胰腺坏死病(AHPND)的效果。灭活疫苗相对存活率41.1-100%,减毒活疫苗96.9-100%但存生物安全挑战,DNA疫苗达96.11%。结论认为疫苗与生物制剂整合策略更有效,但监管、现场条件与病原多样性限制推广。

要点

  • 灭活疫苗安全但保护期短,减毒活疫苗效力最高但存生物安全风险。
  • DNA疫苗与蛋白亚单位疫苗显示一定相对存活率,整合策略优于单一疫苗。
  • 监管障碍、现场条件变异与病原多样性制约疫苗广泛采用。

核心结论

  • 疫苗与生物及天然制剂整合策略在缓解AHPND和减少抗生素依赖方面更有效。
  • 疫苗在改善对虾健康和经济韧性方面有前景,但效力和递送局限需进一步研究。

研究设计与样本

  • 综合综述,分析2009至2025年全球报告及实验室与田间试验证据。
  • 涵盖灭活、减毒活、重组亚单位、DNA疫苗及益生菌、噬菌体、植物化合物、金属纳米颗粒等补充方法。

主要发现

  • AHPND暴发可在放养后10-35天内导致对虾高达100%死亡,部分区域产量下降60%。
  • 灭活疫苗相对存活率41.1-100%,安全但保护期短。
  • 减毒活疫苗相对存活率96.9-100%,保护持久但存生物安全挑战。
  • DNA疫苗相对存活率达96.11%,蛋白亚单位疫苗66.7-82.4%。

关键数值与推荐

  • 灭活疫苗相对存活率41.1-100%。
  • 减毒活疫苗相对存活率96.9-100%。
  • DNA疫苗相对存活率最高96.11%。
  • 蛋白亚单位疫苗相对存活率66.7-82.4%。
  • 噬菌体pVp-1对AHPND菌株感染性90.9%。

临床怎么用

  • 可将疫苗接种与益生菌、噬菌体等生物制剂整合用于AHPND防控。
  • 选择疫苗类型时需权衡效力、保护持久性与生物安全风险。
  • 应减少抗生素依赖,采用综合管理策略应对副溶血弧菌。

局限性

  • 监管障碍限制疫苗广泛采用。
  • 田间条件变异影响疫苗效果。
  • 递送挑战与病原多样性制约疫苗推广。
  • 当前疫苗效力和递送局限需进一步研究优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence of Vibrio parahaemolyticus and Early Mortality Syndrome (EMS), also known as Acute Hepatopancreatic Necrosis Disease (AHPND), severely constrained the sustainability and economic growth of shrimp aquaculture worldwide. The objective of this comprehensive review was to analyze the effectiveness of vaccination as a strategic approach to combat V. parahaemolyticus and control AHPND, focusing on practical alternatives and integrated management methods. The study synthesized global reports from 2009 to 2025, during which AHPND outbreaks led to up to 100 % shrimp mortality within 10-35 days post-stocking, with production decreases of 60 % in some regions and global economic losses estimated at $43 billion from 2010 to 2016. The review examined experimental evidence from laboratory and field trials regarding live attenuated, inactivated, recombinant subunit, and DNA vaccines, as well as complementary approaches including probiotics, phage therapy, plant-based compounds, and metallic nanoparticles. The analysis revealed that inactivated vaccines achieved 41.1-100 % relative percent survival (RPS) and were safe but short-lived, while live attenuated vaccines demonstrated the highest efficacy (96.9-100 % RPS) with prolonged protection, yet posed biosafety challenges. DNA vaccines showed promising results with up to 96.11 % RPS, and protein subunit vaccines achieved 66.7-82.4 % RPS. Certain probiotics such as Lactobacillus plantarum SGLAB01 and bacteriophage pVp-1 significantly improved shrimp survival and immune responses, with pVp-1 showing 90.9 % infectivity against AHPND strains. The study concluded that integrated strategies combining vaccination with biological and natural agents were more effective in mitigating AHPND and reducing antibiotic dependence. However, regulatory hurdles, variable field conditions, delivery challenges, and pathogen diversity limited widespread vaccine adoption. Vaccination shows promise as a sustainable approach to improve shrimp health and economic resilience, but current limitations in efficacy and delivery highlight the need for further research. Vaccine optimization and its integration with management strategies are key to controlling V. parahaemolyticus and Early Mortality Syndrome globally.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sen BK, Ghosh RR, Rahman M, et al. Vaccines as a strategic approach to combat Vibrio parahaemolyticus and control of early mortality syndrome sin shrimp aquaculture: A comprehensive review. Vaccine. 2025. PMID: 41338116. doi:10.1016/j.vaccine.2025.128049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。